200 ADC Biotechs in China Raise Pressure on Daiichi Sankyo; as Global Oncology Race Intensifies

At ASCO 2026 in Chicago, Daiichi Sankyo R&D chief John Tsai outlined a long-term strategy to expand antibody-drug conjugate innovation using AI and data-driven biology. The company plans to build at least two new ADC platforms by 2030 while facing